Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164382 | 0.93 | AKR1C4 (0.43) | SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL8871624 | 0.83 | ALDH1A1 (0.43) | SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL857117 | 0.81 | ALDH1A1 (0.47) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL13315468 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL11259791 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL5498301 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMEN1HSD17B10KDM4E | |
| SCHEMBL13315470 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL6374647 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP3A4KMT2AMEN1HSD17B10 | |
| SCHEMBL11262018 | 0.79 | TDP1 (0.39) | KMT2AMEN1KDM4EALDH1A1NPC1 | |
| SCHEMBL7335337 | 0.79 | HTR3A (0.43) | SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| EP-1641783-B1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2305254-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists for the treatment of gatrointestinal conditions | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| EP-1641782-B1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-03 | — | — | EP | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | BOSMANS JEAN-PAUL RENE MARIE ANDRE | 2010-04-08 | — | — | US | disclosed |
| EP-1638961-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1140915-B1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005003124-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003121-A1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000837-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000837-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-09-25 | — | — | US | disclosed |
| US-6544997-B1 | E.g., hypermotility, irritable bowel syndrome, bowel hypersensitivity and the reduction of pain associated with gastrointestinal hypersensitivity and/or hyperactivity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-1140915-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037461-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | HRH2, ALK, CBR1 | SMN1; SMN2 1422/4885AKR1C4 179/4885AKR1C3 117/4885 |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | HTR4, HTR2B, HTR2C | SMN1; SMN2 1464/4885AKR1C4 2325/4885AKR1C3 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.